Barinthus Biotherapeutics to Delist from Nasdaq September 3 Following Clywedog Merger
Barinthus Biotherapeutics (BRNS) will cease trading on Nasdaq on September 3 following its merger with Clywedog Therapeutics, with shares trading higher as merger completion nears.
What’s your take on this? Join the discussion below.
Read the full analysis on market.news
🇺🇸 United States Stocks M&A biotech nasdaq delisting merger pharma